Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial.

BACKGROUND Right-sided heart failure is the leading cause of death in pulmonary arterial hypertension (PAH). Similar to left heart failure, sympathetic overactivation and β-adrenoreceptor (βAR) abnormalities are found in PAH. Based on successful therapy of left heart failure with β-blockade, the safety and benefits of the nonselective β-blocker/vasodilator carvedilol were evaluated in PAH. METHODS PAH Treatment with Carvedilol for Heart Failure (PAHTCH) is a single-center, double-blind, randomized, controlled trial. Following 1-week run-in, 30 participants were randomized to 1 of 3 arms for 24 weeks: placebo, low-fixed-dose, or dose-escalating carvedilol. Outcomes included clinical measures and mechanistic biomarkers. RESULTS Decreases in heart rate and blood pressure with carvedilol were well tolerated; heart rate correlated with carvedilol dose. Carvedilol-treated groups had no decrease in exercise capacity measured by 6-minute walk, but had lower heart rates at peak and after exercise, and faster heart rate recovery. Dose-escalating carvedilol was associated with reduction in right ventricular (RV) glycolytic rate and increase in βAR levels. There was no evidence of RV functional deterioration; rather, cardiac output was maintained. CONCLUSIONS Carvedilol is likely safe in PAH over 6 months of therapy and has clinical and mechanistic benefits associated with improved outcomes. The data provide support for longer and larger studies to establish guidelines for use of β-blockers in PAH. TRIAL REGISTRATION ClinicalTrials.gov NCT01586156FUNDING. This project was supported by NIH R01HL115008 and R01HL60917 and in part by the National Center for Advancing Translational Sciences, UL1TR000439.

[1]  James D. Thomas,et al.  Metabolic and Functional Evaluation of the Heart and Lungs in Pulmonary Hypertension by Gated 2-[18F]-Fluoro-2-deoxy-D-glucose Positron Emission Tomography , 2017, Pulmonary circulation.

[2]  G. Stark,et al.  Hypoxia sensing through β-adrenergic receptors. , 2016, JCI insight.

[3]  J. Marcus,et al.  Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study , 2016, European Respiratory Journal.

[4]  S. Erzurum,et al.  Flow Cytometric Quantification of Peripheral Blood Cell β-Adrenergic Receptor Density and Urinary Endothelial Cell-Derived Microparticles in Pulmonary Arterial Hypertension , 2016, PloS one.

[5]  S. Erzurum,et al.  Phosphorylation inactivation of endothelial nitric oxide synthesis in pulmonary arterial hypertension. , 2016, American journal of physiology. Lung cellular and molecular physiology.

[6]  N. Voelkel,et al.  The right ventricle and pulmonary hypertension , 2016, Heart Failure Reviews.

[7]  N. Serkova,et al.  Severe pulmonary hypertension is associated with altered right ventricle metabolic substrate uptake. , 2015, American journal of physiology. Lung cellular and molecular physiology.

[8]  R. Dweik,et al.  Outcomes of β-blocker use in pulmonary arterial hypertension: a propensity-matched analysis , 2015, European Respiratory Journal.

[9]  M. Humbert,et al.  Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. , 2015, Journal of the American College of Cardiology.

[10]  N. Voelkel,et al.  Treatment of group I pulmonary arterial hypertension with carvedilol is safe. , 2014, American journal of respiratory and critical care medicine.

[11]  Yiyu Cheng,et al.  A pathway and network review on beta-adrenoceptor signaling and beta blockers in cardiac remodeling , 2014, Heart Failure Reviews.

[12]  James D. Thomas,et al.  Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. , 2013, Annals of the American Thoracic Society.

[13]  B. V. Van Tassell,et al.  Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis , 2013, BMJ.

[14]  R. Dweik,et al.  Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[15]  D. Stewart,et al.  Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. , 2012, The American journal of cardiology.

[16]  Nico Westerhof,et al.  Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. , 2011, Journal of the American College of Cardiology.

[17]  M. Bristow.  Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. , 2011, Circulation research.

[18]  N. Morrell,et al.  18FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: A proof-of-principle study , 2011, Pulmonary circulation.

[19]  N. Ozdemir,et al.  Increased Right Ventricular Glucose Metabolism in Patients With Pulmonary Arterial Hypertension , 2011, Clinical nuclear medicine.

[20]  M. Raza.  Adrenergic Receptor Blockade Reverses Right Heart Remodeling and Dysfunction in Pulmonary Hypertensive Rats , 2011 .

[21]  C. Francart,et al.  Interest of b-blockers in patients with right ventricular systemic dysfunction , 2010 .

[22]  R. Naeije,et al.  Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. , 2010, American journal of respiratory and critical care medicine.

[23]  A. Peacock,et al.  Pulmonary hypertension: a contraindication to the use of β-adrenoceptor blocking agents , 2010, Thorax.

[24]  I. Haber,et al.  The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle , 2009, Journal of Molecular Medicine.

[25]  The effect of beta-blockade on heart rate recovery following exercise stress echocardiography. , 2008, Preventive cardiology.

[26]  R. Schrier,et al.  Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure? , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[27]  M. Gomberg-Maitland,et al.  United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[28]  Robert J. Lefkowitz,et al.  A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling , 2007, Proceedings of the National Academy of Sciences.

[29]  Raed A Dweik,et al.  Alterations of cellular bioenergetics in pulmonary artery endothelial cells , 2007, Proceedings of the National Academy of Sciences.

[30]  J. Violin,et al.  A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Humbert,et al.  Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. , 2006, Gastroenterology.

[32]  D. Meads,et al.  The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A Measure of Health-Related Quality of Life and Quality of Life for Patients with Pulmonary Hypertension , 2006, Quality of Life Research.

[33]  R. Naeije,et al.  Increased Sympathetic Nerve Activity in Pulmonary Artery Hypertension , 2004, Circulation.

[34]  G. Feuerstein,et al.  Pharmacology of Carvedilol: Rationale for Use in Hypertension, Coronary Artery Disease, and Congestive Heart Failure , 1997, Cardiovascular Drugs and Therapy.

[35]  L. Dobrucki,et al.  Third-Generation &bgr;-Blockers Stimulate Nitric Oxide Release From Endothelial Cells Through ATP Efflux: A Novel Mechanism for Antihypertensive Action , 2003, Circulation.

[36]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[37]  A. Zeiher,et al.  Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. , 2000, Journal of the American College of Cardiology.

[38]  K. Kangawa,et al.  Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.

[39]  R Dietz,et al.  Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.

[40]  M. Bristow.  β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[41]  M. Bristow.  beta-adrenergic receptor blockade in chronic heart failure. , 2000, Circulation.

[42]  S. Steinberg.  The molecular basis for distinct beta-adrenergic receptor subtype actions in cardiomyocytes. , 1999, Circulation research.

[43]  M. Lauer,et al.  Heart-rate recovery immediately after exercise as a predictor of mortality. , 1999, The New England journal of medicine.

[44]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[45]  G. Bellomo,et al.  Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. , 1996, Journal of cardiovascular pharmacology.

[46]  S. Rich,et al.  Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. , 1995, Journal of the American College of Cardiology.

[47]  L. Wilkins.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.

[48]  J. Skoularigis,et al.  Pulmonary hypertension is a contraindication to beta-blockade in patients with severe mitral stenosis. , 1993, American heart journal.

[49]  Hung‐Yuan Cheng,et al.  Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. , 1992, The Journal of pharmacology and experimental therapeutics.

[50]  L. Mestroni,et al.  Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. , 1992, The Journal of clinical investigation.

[51]  K Caidahl,et al.  Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. , 1989, Circulation.

[52]  J L Benovic,et al.  Functional desensitization of the isolated beta-adrenergic receptor by the beta-adrenergic receptor kinase: potential role of an analog of the retinal protein arrestin (48-kDa protein). , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Perry,et al.  Elevation of beta-adrenergic receptor density in human lymphocytes after propranolol administration. , 1980, The Journal of clinical investigation.